CA2355835A1 - System and method for controlling tissue ablation - Google Patents
System and method for controlling tissue ablation Download PDFInfo
- Publication number
- CA2355835A1 CA2355835A1 CA002355835A CA2355835A CA2355835A1 CA 2355835 A1 CA2355835 A1 CA 2355835A1 CA 002355835 A CA002355835 A CA 002355835A CA 2355835 A CA2355835 A CA 2355835A CA 2355835 A1 CA2355835 A1 CA 2355835A1
- Authority
- CA
- Canada
- Prior art keywords
- tissue
- accordance
- ablative
- interface
- abnormal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/1206—Generators therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00017—Electrical control of surgical instruments
- A61B2017/00022—Sensing or detecting at the treatment site
- A61B2017/00057—Light
- A61B2017/00061—Light spectrum
Abstract
A control system (100), and method for controlling tissue ablation, uses an optical time domain reflectometer data to differentiate abnormal tissue from normal tissue; and to control ablation of abnormal tissue by controlling a tissue ablative apparatus (108). Using data provided by an interferometric apparatus (106), the control system (100) provides control signals to the tissue ablative apparatus (100), controlling activation of the tissue ablati on apparatus (108) so that normal tissue is left untreated while abnormal tissu e is ablated.
Description
SYSTEM AND METHOD FOR
CONTROLLING TISSUE ABLATION
BACKGROUND OF THE INVENTION
5 This invention relates generally to systems and methods for controlling medical devices, and more particularly, to a control system and methods for controlling tissue ablation.
Many medical treatments involve the removal of diseased or damaged tissue from within the body. For example, common surgical practice requires the 10 excision of tumors, cysts, and polyps, whiclh may appear in any area of the body, and the removal of atherosclerotic plaque from arteries. Classical surgical techniques require a properly trained surgeon to directly view the tissue being treated to determine which, and how much, of the tissue can safely be removed.
This type of procedure is highly invasive and typically requires a lengthy 15 recovery period for the patient.
More modern, less invasive surgical tissue removal techniques are known.
Generally these techniques greatly benefit the patient, but present new challenges for the surgeon. For example, catheters, endoscopes and laparoscopes are now commonly used for a variety of surgical procedures and require minimal entry 20 into the body. Use of these techniques generally decreases surgical trauma and recovery time, and improves outcome, but also incur significant disadvantages for the surgeon. Particularly, such techniques impair visualization of the affected region and substantially limit surgical working space. For example, optical fiber endoscopes are known but cannot be used in a blood field without 25 first clearing the blood with a saline solution. Ultrasound probes are known but often produce false echoes when used for looking forward through, for example, the lumen of an artery. Fluoroscopy is known but is two-dimensional and exposes the patient and medical personnel to various forms of radiation.
CONTROLLING TISSUE ABLATION
BACKGROUND OF THE INVENTION
5 This invention relates generally to systems and methods for controlling medical devices, and more particularly, to a control system and methods for controlling tissue ablation.
Many medical treatments involve the removal of diseased or damaged tissue from within the body. For example, common surgical practice requires the 10 excision of tumors, cysts, and polyps, whiclh may appear in any area of the body, and the removal of atherosclerotic plaque from arteries. Classical surgical techniques require a properly trained surgeon to directly view the tissue being treated to determine which, and how much, of the tissue can safely be removed.
This type of procedure is highly invasive and typically requires a lengthy 15 recovery period for the patient.
More modern, less invasive surgical tissue removal techniques are known.
Generally these techniques greatly benefit the patient, but present new challenges for the surgeon. For example, catheters, endoscopes and laparoscopes are now commonly used for a variety of surgical procedures and require minimal entry 20 into the body. Use of these techniques generally decreases surgical trauma and recovery time, and improves outcome, but also incur significant disadvantages for the surgeon. Particularly, such techniques impair visualization of the affected region and substantially limit surgical working space. For example, optical fiber endoscopes are known but cannot be used in a blood field without 25 first clearing the blood with a saline solution. Ultrasound probes are known but often produce false echoes when used for looking forward through, for example, the lumen of an artery. Fluoroscopy is known but is two-dimensional and exposes the patient and medical personnel to various forms of radiation.
Impaired visualization of the surgical field makes removal of diseased tissue difficult. In particular, the use of high energy tissue ablation devices such as those powered by lasers, radio frequency transmission, microwaves and the like, is risky under conditions of impaired visualization because poor 5 discrimination of healthy tissue from diseased tissue can result in damage of healthy tissue. Accordingly, a surgeon operating such an ablation device must advance it extremely cautiously, perhaps rni~ssing diseased tissue which should be removed .
It would therefore be desirable to provide a precise and reliable method 10 for controlling the activation and advancement of tissue ablative devices.
It would also be desirable to provide an improved method for visualizing internal body tissues being treated with minimally invasiive tissue ablative devices. It would also be desirable to provide an improved meahod and apparatus for differentiation of abnormal tissue from normal tissue.
IS BRIEF SUMMARY OF THE INVENTION
In an exemplary embodiment, a method for controlling tissue ablation uses optical time domain reflectometry data to differentiate abnormal tissue from normal tissue, to control ablation of abnormal tissue by controlling the delivery 20 of energy to a tissue ablation element. Using data provided by an interferometric apparatus, a control system provides control signals to tissue ablative apparatus and controls activation of the tissue ablation apparatus so that normal tissue is left untreated while abnormal tissue is ablated.
In one aspect, the present invention is directed to using interference data 25 to identify an interface between abnormal tissue and healthy or normal tissue, and altering the delivery of energy to the tissue ablative apparatus in response to identification of an interface. In one embodiment, the control system includes a _3_ microprocessor and an energy controller. The control system is coupled to an interferometric apparatus for providing interfering light beams which produce the interferometric data. More specifically, for example, a low coherence light source producing a light beam is coupled to a beam sputter which splits the beam 5 into two beams, a first or reference beam, and a second or sampling beam, which are transmitted respectively down a first optical fiber, and a second optical fiber. The second optical fiber extends through the lumen of a support member such as a catheter so that a distal, sampling end of the second optical fiber can be positioned near a sample, such as an internal body tissue to be inspected. The 10 first optical fiber is positioned outside the body. The first beam is reflected at the distal or free end of the first optical fiber by a reflector coupled thereto, while the second beam is reflected at the distal samfrling end by the sample. The lengths of the first and second optical fibers are adjustable with, for example, a piezoelectric coil. The reflected beasns interfere with one another when IS recombined at the beam splitter. The path length difference between the recombined beams produces a pattern of interference which is detected by a detecting element coupled to the beam splatter. The detecting element provides the interference data to the control system, in which the microprocessor generates a psuedoimage of the sample, and detects interfaces between normal and 20 abnormal tissue. In response to the detection of such an interface; the microprocessor generates and supplies control signals to the energy controller, which accordingly alters the delivery of energy to the tissue ablative apparatus.
In another aspect, the present invention is directed to providing a psuedoimage of a tissue sample for visual display to an individual who is 25 manually advancing a tissue ablative element of the tissue ablative apparatus. In an exemplary embodiment, the microprocessor is coupled to an output display device such as a monitor. The psuedoimage data generated by the microprocessor is displayed on the monii:or so that the operator has a visual image while manually advancing the tissue ablative element. The operator can advance while watching the image until, for example, the control system detects an interface and alters the delivery of enerl;y to the tissue ablative apparatus.
The control system and method provide for minimally invasive control of tissue ablation. Further, the system provides high resolution image data so that 5 tissue ablation can be controlled at a very fine scale. In addition, the system and method provide for improved differentiation of abnormal tissue from normal tissue.
BRIEF DESCRIPTION OF THE DRAWINGS
10 Figure 1 is a schematic illustration of a control system for controlling tissue ablation.
Figure 2 is a schematic illustration of the principles of optical coherence domain reflectometry on which the control system for controlling tissue ablation is based.
15 Figure 3 is a graph showing the scattering effects on a light beam of a diseased artery having a layer of atheroscle;otic plaque.
Figure 4 is a graph showing the scattering effects on a light beam of a healthy artery.
DETAILED DESCRIPTION OF THE IN'JENTION
20 Figure 1 is a schematic illustration of an exemplary embodiment of a control system 100. Generally, control system 100 includes a microprocessor 102 coupled to an energy controller 104, ;end is shown in Figure 1 coupled to interoferometric apparatus 106 and tissue abllative apparatus 108.
Microprocessor 102, utilizing an output supplied by interferometric apparatus 106, generates an 25 output signal which is supplied to energy controller 104. Using the output signal supplied by microprocessor 102, energy controller 104 alters, or adjusts, an -s-energy signal supplied to tissue ablative apparatus 10$. Additionally, the output of microprocessor 102 can be used to generate a pseudoimage on an output device as described below.
A control algorithm as described below may be implemented in s microprocessor 102 and practiced using data collected by interoferometric apparatus 106. It will be apparent to those skilled in the art that, of course, such an algorithm may be practiced with many alternative microprocessors, and is not limited to practice only in connection with chose integrated circuits referred to in the art as microprocessors. Therefore, and as used herein, the term 10 microprocessor refers to microcompui:ers, processors, microcontrollers, application-specific integrated circuits, and other programmable circuits. In addition, the present application is directed to the control methods and system as described below in more detail. It should be understood that such methods and systems should not be limited to a particular interferometric apparatus or tissue 1 s ablative apparatus as described below in an exemplary embodiment.
Interferometric apparatus 106 typically includes a light source 1 IO coupled to a beam splitter 112. In one embodiment, light source 110 is a low coherence light source having a power of about 100 microWatts to about 2s milliWatts.
While the light source may be varied., sources that emit short coherent 20 wavelengths of about 0.7 to about 2.0 microns are more desirable than those emitting longer wavelengths because shorner wavelengths allow better imaging properties and penetration. However, the liight source may be varied to adjust the wavelength of the light to between about 0.3 to about 5.0 microns, to optimize the imaging resolution of the tissue expeci;ed to be encountered. For example, 2s light of a wavelength of about 1.3 microns has been found to be optimal for penetrating through atherosclerotic plaque and imaging the adventitia and media inside of a diseased artery. A first, reference optical fiber 114 is coupled at a proximal end I16 to beam sputter 112, and has a free or distal end 11$ with a reflector 120, such as a mirrored surface, .coupled thereto. A second, sampling -G-optical fiber 122 is coupled at a proximal end 124 to beam splitter 112, and has a distal sampling end 126 for placement near or adjacent an internal body tissue T. To adjust the relative lengths of first optical fiber 114 and second optical fiber 122, f=irst optical fiber 114 is wrapped around a first piezoelectric coil 128, 5 and second optical fiber 122 is wrapped around a second piezoelectric coil 130.
Other devices or elements for adjusting thf; relative lengths of the optical fibers are known in the art. Second optical fiber 122 extends through a lumen of a support member 132 such as, for example, a catheter or an endoscope. Beam splitter 112 has an output coupled to a detecaing element 134 which includes, for 10 example, a photodetector, a demodulator and an analog digitizer (not shown).
Detecting element 134 has an output coupled to microprocessor 102.
Microprocessor 102 can be further coupled to an output display device 136 such as a computer monitor for visual display oi" data.
First optical fiber 114 and second optical fiber 122 are, for example, a 15 type commonly used in medical imaging, having a total outside diameter of less than about 150 microns. In one embodiment, suitable optical fibers are fabricated from drawn or extruded glass or plastic having a central core and a cladding of a lower refractive index material to promote; internal reflection. The diameter of the optical fibers may be varied to optimize transmission of the particular 20 wavelength of light chosen, and to obtain clearance through the lumen of support member 132. For example, for light having a wavelength of 1300 nm, a single mode optical fiber having a diameter of 125 microns with a total outside diameter of about 150 microns would be suitable. Optical fibers having smaller diameters of about 80 microns are also available and can be used when greater clearance 25 through the lumen of support member 132 is desired, or alternatively, bundles of optical fibers may be used.
Tissue ablative apparatus 108, in one embodiment, includes an energy source I38 such as a laser energy source, for tissue ablation. Energy source is coupled to a tissue ablative device i40 at a proximal end 142 of tissue ablative _'7_ element 140. Tissue ablative element 140 c;an be, for example, a laser catheter.
In any case, tissue ablative element 140 has a distal end 144 and extends through support member 132 so that distal end 144 can be positioned near tissue T.
In an exemplary embodiment, energy source 138 for tissue ablative S element 140 is a laser source, and tissue ablative element 140 is a laser catheter including at least one optical fiber (not shown) extending through support member 132 for transmitting a laser beam from the laser source to tissue T, so that tissue inspection and ablation can be accomplished simultaneously. In an alternative embodiment in which energy ;source 138 is again a laser source, 10 ablative element 140 shares first optic fiber 114 with interoferometric apparatus 10b, and input to first optic fiber 114 is switched with a second beam splitter (not shown) between interoferometric apparatus 106 and the laser source so that inspection of tissue T and ablation occur alternately. Alternatively, tissue ablative element 140 may be, for example, a radio frequency device, mechanical 15 cutting or atherectomy device, ultrasound device, microwave device or other minimally invasive tissue ablation device. Energy source i38 can accordingly be a radiofrequency source, source for mechanical energy, ultrasound source, microwave source, or the like.
Figure 2 is a schematic illustration of the principles of optical coherence 20 domain reflectometry on which control systf:m 100 is based. In use, for example, support member 132 is positioned internally in a body, for example by inserting into a body passage or surgical incision, so that second optic fiber distal end 126 is positioned within the body near tissue T to be inspected. First optic uber is positioned external to the body. Light source 110 is energized to produce a 25 light beam B which is transmitted to beam splitter 112. Beam sputter 112 is configured to split beam B from light source 110 into a reference beam Bt and a sampling beam B2. Beam splitter 112 directs reference beam B, along first optical fiber 114 toward reflector 120, and second beam BZ along second optical fiber 122 toward tissue T. B, is reflected hack along first optical fiber 114 by _g_ reflector 120, and Bz is reflected back along; second optical fiber 122 by tissue T.
B, and Bz are recombined at beam splitter 1 i2 and interfere constructively with each other when their respective path lengths are equivalent with one another. The distance over which interference occurs can be determined by the coherence function of the light source. Typically the coherence length is about microns for a low coherence light source having a power of about 100 microWatts to about 25 milliWatts.
The optical path length of light beam BZ depends on the length of second optical fiber 122. The optical path length of light beam B, depends on the length 10 of first optical fiber 114 and the distance in the tissue from where the light is scattered (reflected), adjusted for the change in the group refractive index difference of the tissue. Referring again to Figure 1, the optical distances along optical fibers 114 and I22 can be varied by actuating piezoelectric coils 128 and 130. By continually varying the optical path lengths, the tissue depth can be 15 scanned such that the intensity of light scattering from a series of specific depths can be measured. For example, when the: optical path length of B, is 0.5 mm longer than the optical path length of B2, the intensity of light scattered from an optically equivalent (adjusted for the change in group refractive indices) depth of 0.5 mm in the tissue is measured. The optical path lengths are continually varied, and intensity of scattered light measured to develop a function of scattering intensity versus distance. Thus, the interferometric technique precisely measures very small distances and thicknesses, so that a high resolution image of tissue T can be formed, providing on-line, high resolution information to determine if ablative device 140 can be safely enabled or advanced. Further details an the interferometric technique and interferometric apparatus are described in co-pending U.S. Patent Application Serial Nos. 09/060,487 (filed April 15, 1998), which is assigned to the present assignee, and which is incorporated herein, in its entirety, by ref<;rence. In alternate embodiments, in place of interferometric apparatus 106, control system 100 is instead coupled to an apparatus which uses a different technique for analyzing reflected light, such as Roman or Rayleigh spectroscopy, induced fluorescence, or other linear or non linear techniques. For example, when coupled to a spectroscopic apparatus, microprocessor 102 uses analysis of spectroscopic data to identify an interface 5 between abnormal and normal tissue.
Figure 3 is a graph showing the scai:tering effects on light beam B~ of an abnormal tissue: an area of plaque 302 in a diseased artery. The graph shows intensity of reflected light in decibels as a function of distance from distal end 126 of second optical fiber 122. On such a graph, plaque area 302 is I0 distinguishable from an area 304 of normal, healthy artery tissue by an increased and steady decay of reflected light intensity as a function of distance. More specifically, by determining the slope of the decay, abnormal tissue is identified as described below in more detail. The steady decay exhibited in area 302 relative to area 304 is attributable to the relatively unorganized structure of 15 abnormal tissue, in this case plaque, which tends to scatter light in randorn directions, thereby decreasing the intensity of reflected light transmitted back through second optical fiber 122. The relatively more organized structure of normal tissue, in this case healthy arterial wail, scatters the light in a birefringent or anisotropic pattern so that relatively nnore light is reflected back through 20 second optical fiber 122.
Microprocessor 102 supplies control signals to energy controller 104.
More specifically, the control algorithm detects the presence of abnormal tissue by examining the rate of decay of reflected light intensity as a function of distance from distal end I26 of second optical fiber 122. For example, microprocessor 25 102. samples the reflected light at about 10 hertz, and generates a sliding average of multiple points, for example averaging the intensity value over a window of about 8 to about 30 points at a time. The sliding average identifies inflection points in the function which represent a true or actual change in the slope of the function, as opposed to noise. An actual change in slope identifies an interface WO 00/41611 PCT/US00l00460 between normal tissue and abnormal tissue. For example, using a light source of about 100 microWatts, emitting light at a wavelength of 1300 nm, normal tissue is identified by regions of the function having a slope of less than about -75 dB/mm. Regions of the function having; a slope within the range of about -5 dBlmm to about -I50 dBlmm indicate a soft plaque such as a fatty or lipid plaque. A slope within about -150 dB/mm to about -200 dB/mm would indicate a calcified plaque, while a slope greater than about -200 dB/mm indicates air or blood. The algorithm is, for example, a simple go/no-go algorithm in which the inflection points between regions of the function having different slopes are used 10 to determine the state of control signals supplied to energy controller I04 to either enable or disenable tissue ablative device 140. In alternative embodiments, the algorithm can be configured to perform a more complex pattern recognition or noise analysis which identifies the chang<a in reflected light which characterize the interfaces between normal and abnormal tissue.
15 Far example, Figure 3 shows reflected light intensity as a function of distance in an artery, using a light source of about 100 microWatts emitting light at a wavelength of 1300 nm. From aboul: 0.100 mm to about 0.200 mm from distal end I26 of second optical Fiber 122 ., the slope of the function is less than about -75 dBlmm, which indicates normal, healthy tissue in area 304. At 20 approximately 0.200 mm from distal end 126, the slope of the function changes, which microprocessor 102 identifies as an interface between normal tissue (arterial wall) and abnormal tissue, in this case a plaque. The slope of the function from about 0.200 mm to about 0.:?75 mm, plaque area 302, from distal end 126 is about -I00 dBlmm. This slope falls within the range of about -75 25 dB/mm to about -150 dB/mm, which indicates a soft plaque such as a fatty or lipid plague. At about 0.275 mm from distal end I26, the slope of the function again changes, and microprocessor 102 idf;ntifies an interface. In this case, the slope of the function from about 0.275 mrn to about 0.350 mm from distal end 126 is about -267 dB/rnm, indicating air or blood, so that microprocessor I02 identifies an interface between the end of a plaque and air or blood at 0.275 mm from distal end 126. A change in slope representing a decrease in decay of reflected light as a function of distance (i.e. a decrease in slope), not shown, would identify an interface between the end of a plaque and normal tissue.
5 Figure 4 shows the intensity of reflected light as a function of distance in a normal, healthy artery, using a light source of about 100 microWatts emitting light at a wavelength of 1300 nm. The function from about 0.100 mm to about 0.230 mm from distal end 126 has a slope c~f about -70 dBlmm, indicating normal tissue. At about 0.230 mm, the slope of the function from about 0.230 mm to 10 about 0.290 mm increases to about -400 db/mm, indicating blood in the artery.
In typical use, for example, distal end 144 of disenabled tissue ablative element 140 is positioned within a normal section of artery and advanced along a longitudinal axis of the artery defined by the length of second optical fiber 122.
The start of an area or region of abnormal tissue, such as an atherosclerotic I S plaque, is identified when microprocessor 102 identifies a normal tissue/abnormal tissue interface ahead of second optic fiber distal end 126 (and distal end 144 of tissue ablative element 140). Tissue ablatiive element distal end 144 is advanced just past the interface, e.g., the start of the plaque, and then microprocessor 102 supplies signals to energy controller 104 to activate energy source 138 so that 20 tissue ablative device 140 is enabled and the abnormal tissue (plaque) is ablated.
In one embodiment, to insure that normal tissue is not inadvertently damaged, a small area or region of plaque behind the area where ablative element 140 is first enabled can be left remaining. Tissue ablative element 140 is advanced through the plaque, and can be safely enabled as long as no tissue interface between the 25 abnormal tissue (plaque) and narmal tissue is detected by microprocessor 102.
In one embodiment, when microprocessor 102, using the output of interferometric apparatus 106, identifies an interface between the abnormal (plaque) tissue and normal tissue ahead of second optic fiber distal end 126, microprocessor 102 accordingly supplies signals to energy controller 104 to WO fl0/41611 PCT/US00/fl0460 _12_ deactivate energy source 138 so that tissuf: ablative element 140 is disenabled before reaching the normal tissue, and normal tissue is undamaged by tissue ablative element 140. A small area or region of plaque at the end of the plaque relative to tissue ablative element distal end 144 may be left remaining, to insure 5 that normal tissue is undamaged by tissue ablative element 140. However, it should be recognized by those skilled in the art that the relative position of tissue ablative element 140 with respect to an atrnormal/normal or normal/abnormal tissue interface, at which tissue ablative element 140 is enabled or disenabled, can be varied. Further, the amount of energy delivered to tissue ablative element 10 can be adjusted depending on whether a soft plaque or calcified plaque has been identified. For example, if a calcified plaque is identified, a lower amount of energy can first be delivered to tissue ablative element 140. If the plaque is not ablated using a lower amount of energy, then the energy can be upwardly adjusted to ablate the calcified plaque.
15 In an exemplary embodiment, control system 100 performs real-time control of tissue ablation without further input from an operator. In an alternative embodiment, control system 100 is further linked to a stepping motor or the like, which is linked to tissue ablative element 140 and to microprocessor 102. The stepping motor responds to control signals from microprocessor 102 20 by advancing or retracting tissue ablative element 140 so that both enablement and advancement of tissue ablative element 140 are automatically controlled by control system 100. For example, after abnormal tissue has been detected and tissue ablative element 140 enabled, tissue ablative element 140 is advanced as long as a tissue interface between the abnormal tissue and normal tissue is not 25 detected. Tissue ablative element 140 continues to advance until such a tissue interface is identified, indicating normal tissue ahead of tissue ablative element 140. Once such an interface is identified, tissue ablative element 140 is disenabled and can be retracted. In an alternative method of use, a manual operator of tissue ablative element 140 many view the pseudoimage on output display device 136 for real-time imaging of the tissue so that the operator can accordingly respond by manually activating or deactivating the energy controller, or by manually advancing or retracting ablative element 140. Because second optical fiber 122 can be used simultaneously and side-by-side with tissue ablative element 140, the system can provide continuous, high resolution imaging.data to the operator as tissue ablative element 140 is advanced.
The control system thus provides high resolution imaging data for automated or manual control of minimally invasive tissue ablative devices. In an alternative embodiment, a variety of tissue ablative modalities, devices and probes, including radio frequency devices, microwave devices, ultrasound devices, mechanical cutting or atherectomy devices and laser catheters, as known in the art, are used with control system 100. Further, the guidance system can be used simultaneously with the tissue ablative element to provide continuous online information regarding the tissue being treated, as the tissue ablative element is being advanced.
From the preceding description of various embodiments of the present invention, it is evident that the objects of the invention are attained.
Although the invention has been described and illustrated in detail, it is to be clearly understood that the same is intended by way of illustration and example only and is not to be taken by way of limitation. Accordingly, the spirit and scope of the invention are to be limited only by the terms of the appended claims.
It would therefore be desirable to provide a precise and reliable method 10 for controlling the activation and advancement of tissue ablative devices.
It would also be desirable to provide an improved method for visualizing internal body tissues being treated with minimally invasiive tissue ablative devices. It would also be desirable to provide an improved meahod and apparatus for differentiation of abnormal tissue from normal tissue.
IS BRIEF SUMMARY OF THE INVENTION
In an exemplary embodiment, a method for controlling tissue ablation uses optical time domain reflectometry data to differentiate abnormal tissue from normal tissue, to control ablation of abnormal tissue by controlling the delivery 20 of energy to a tissue ablation element. Using data provided by an interferometric apparatus, a control system provides control signals to tissue ablative apparatus and controls activation of the tissue ablation apparatus so that normal tissue is left untreated while abnormal tissue is ablated.
In one aspect, the present invention is directed to using interference data 25 to identify an interface between abnormal tissue and healthy or normal tissue, and altering the delivery of energy to the tissue ablative apparatus in response to identification of an interface. In one embodiment, the control system includes a _3_ microprocessor and an energy controller. The control system is coupled to an interferometric apparatus for providing interfering light beams which produce the interferometric data. More specifically, for example, a low coherence light source producing a light beam is coupled to a beam sputter which splits the beam 5 into two beams, a first or reference beam, and a second or sampling beam, which are transmitted respectively down a first optical fiber, and a second optical fiber. The second optical fiber extends through the lumen of a support member such as a catheter so that a distal, sampling end of the second optical fiber can be positioned near a sample, such as an internal body tissue to be inspected. The 10 first optical fiber is positioned outside the body. The first beam is reflected at the distal or free end of the first optical fiber by a reflector coupled thereto, while the second beam is reflected at the distal samfrling end by the sample. The lengths of the first and second optical fibers are adjustable with, for example, a piezoelectric coil. The reflected beasns interfere with one another when IS recombined at the beam splitter. The path length difference between the recombined beams produces a pattern of interference which is detected by a detecting element coupled to the beam splatter. The detecting element provides the interference data to the control system, in which the microprocessor generates a psuedoimage of the sample, and detects interfaces between normal and 20 abnormal tissue. In response to the detection of such an interface; the microprocessor generates and supplies control signals to the energy controller, which accordingly alters the delivery of energy to the tissue ablative apparatus.
In another aspect, the present invention is directed to providing a psuedoimage of a tissue sample for visual display to an individual who is 25 manually advancing a tissue ablative element of the tissue ablative apparatus. In an exemplary embodiment, the microprocessor is coupled to an output display device such as a monitor. The psuedoimage data generated by the microprocessor is displayed on the monii:or so that the operator has a visual image while manually advancing the tissue ablative element. The operator can advance while watching the image until, for example, the control system detects an interface and alters the delivery of enerl;y to the tissue ablative apparatus.
The control system and method provide for minimally invasive control of tissue ablation. Further, the system provides high resolution image data so that 5 tissue ablation can be controlled at a very fine scale. In addition, the system and method provide for improved differentiation of abnormal tissue from normal tissue.
BRIEF DESCRIPTION OF THE DRAWINGS
10 Figure 1 is a schematic illustration of a control system for controlling tissue ablation.
Figure 2 is a schematic illustration of the principles of optical coherence domain reflectometry on which the control system for controlling tissue ablation is based.
15 Figure 3 is a graph showing the scattering effects on a light beam of a diseased artery having a layer of atheroscle;otic plaque.
Figure 4 is a graph showing the scattering effects on a light beam of a healthy artery.
DETAILED DESCRIPTION OF THE IN'JENTION
20 Figure 1 is a schematic illustration of an exemplary embodiment of a control system 100. Generally, control system 100 includes a microprocessor 102 coupled to an energy controller 104, ;end is shown in Figure 1 coupled to interoferometric apparatus 106 and tissue abllative apparatus 108.
Microprocessor 102, utilizing an output supplied by interferometric apparatus 106, generates an 25 output signal which is supplied to energy controller 104. Using the output signal supplied by microprocessor 102, energy controller 104 alters, or adjusts, an -s-energy signal supplied to tissue ablative apparatus 10$. Additionally, the output of microprocessor 102 can be used to generate a pseudoimage on an output device as described below.
A control algorithm as described below may be implemented in s microprocessor 102 and practiced using data collected by interoferometric apparatus 106. It will be apparent to those skilled in the art that, of course, such an algorithm may be practiced with many alternative microprocessors, and is not limited to practice only in connection with chose integrated circuits referred to in the art as microprocessors. Therefore, and as used herein, the term 10 microprocessor refers to microcompui:ers, processors, microcontrollers, application-specific integrated circuits, and other programmable circuits. In addition, the present application is directed to the control methods and system as described below in more detail. It should be understood that such methods and systems should not be limited to a particular interferometric apparatus or tissue 1 s ablative apparatus as described below in an exemplary embodiment.
Interferometric apparatus 106 typically includes a light source 1 IO coupled to a beam splitter 112. In one embodiment, light source 110 is a low coherence light source having a power of about 100 microWatts to about 2s milliWatts.
While the light source may be varied., sources that emit short coherent 20 wavelengths of about 0.7 to about 2.0 microns are more desirable than those emitting longer wavelengths because shorner wavelengths allow better imaging properties and penetration. However, the liight source may be varied to adjust the wavelength of the light to between about 0.3 to about 5.0 microns, to optimize the imaging resolution of the tissue expeci;ed to be encountered. For example, 2s light of a wavelength of about 1.3 microns has been found to be optimal for penetrating through atherosclerotic plaque and imaging the adventitia and media inside of a diseased artery. A first, reference optical fiber 114 is coupled at a proximal end I16 to beam sputter 112, and has a free or distal end 11$ with a reflector 120, such as a mirrored surface, .coupled thereto. A second, sampling -G-optical fiber 122 is coupled at a proximal end 124 to beam splitter 112, and has a distal sampling end 126 for placement near or adjacent an internal body tissue T. To adjust the relative lengths of first optical fiber 114 and second optical fiber 122, f=irst optical fiber 114 is wrapped around a first piezoelectric coil 128, 5 and second optical fiber 122 is wrapped around a second piezoelectric coil 130.
Other devices or elements for adjusting thf; relative lengths of the optical fibers are known in the art. Second optical fiber 122 extends through a lumen of a support member 132 such as, for example, a catheter or an endoscope. Beam splitter 112 has an output coupled to a detecaing element 134 which includes, for 10 example, a photodetector, a demodulator and an analog digitizer (not shown).
Detecting element 134 has an output coupled to microprocessor 102.
Microprocessor 102 can be further coupled to an output display device 136 such as a computer monitor for visual display oi" data.
First optical fiber 114 and second optical fiber 122 are, for example, a 15 type commonly used in medical imaging, having a total outside diameter of less than about 150 microns. In one embodiment, suitable optical fibers are fabricated from drawn or extruded glass or plastic having a central core and a cladding of a lower refractive index material to promote; internal reflection. The diameter of the optical fibers may be varied to optimize transmission of the particular 20 wavelength of light chosen, and to obtain clearance through the lumen of support member 132. For example, for light having a wavelength of 1300 nm, a single mode optical fiber having a diameter of 125 microns with a total outside diameter of about 150 microns would be suitable. Optical fibers having smaller diameters of about 80 microns are also available and can be used when greater clearance 25 through the lumen of support member 132 is desired, or alternatively, bundles of optical fibers may be used.
Tissue ablative apparatus 108, in one embodiment, includes an energy source I38 such as a laser energy source, for tissue ablation. Energy source is coupled to a tissue ablative device i40 at a proximal end 142 of tissue ablative _'7_ element 140. Tissue ablative element 140 c;an be, for example, a laser catheter.
In any case, tissue ablative element 140 has a distal end 144 and extends through support member 132 so that distal end 144 can be positioned near tissue T.
In an exemplary embodiment, energy source 138 for tissue ablative S element 140 is a laser source, and tissue ablative element 140 is a laser catheter including at least one optical fiber (not shown) extending through support member 132 for transmitting a laser beam from the laser source to tissue T, so that tissue inspection and ablation can be accomplished simultaneously. In an alternative embodiment in which energy ;source 138 is again a laser source, 10 ablative element 140 shares first optic fiber 114 with interoferometric apparatus 10b, and input to first optic fiber 114 is switched with a second beam splitter (not shown) between interoferometric apparatus 106 and the laser source so that inspection of tissue T and ablation occur alternately. Alternatively, tissue ablative element 140 may be, for example, a radio frequency device, mechanical 15 cutting or atherectomy device, ultrasound device, microwave device or other minimally invasive tissue ablation device. Energy source i38 can accordingly be a radiofrequency source, source for mechanical energy, ultrasound source, microwave source, or the like.
Figure 2 is a schematic illustration of the principles of optical coherence 20 domain reflectometry on which control systf:m 100 is based. In use, for example, support member 132 is positioned internally in a body, for example by inserting into a body passage or surgical incision, so that second optic fiber distal end 126 is positioned within the body near tissue T to be inspected. First optic uber is positioned external to the body. Light source 110 is energized to produce a 25 light beam B which is transmitted to beam splitter 112. Beam sputter 112 is configured to split beam B from light source 110 into a reference beam Bt and a sampling beam B2. Beam splitter 112 directs reference beam B, along first optical fiber 114 toward reflector 120, and second beam BZ along second optical fiber 122 toward tissue T. B, is reflected hack along first optical fiber 114 by _g_ reflector 120, and Bz is reflected back along; second optical fiber 122 by tissue T.
B, and Bz are recombined at beam splitter 1 i2 and interfere constructively with each other when their respective path lengths are equivalent with one another. The distance over which interference occurs can be determined by the coherence function of the light source. Typically the coherence length is about microns for a low coherence light source having a power of about 100 microWatts to about 25 milliWatts.
The optical path length of light beam BZ depends on the length of second optical fiber 122. The optical path length of light beam B, depends on the length 10 of first optical fiber 114 and the distance in the tissue from where the light is scattered (reflected), adjusted for the change in the group refractive index difference of the tissue. Referring again to Figure 1, the optical distances along optical fibers 114 and I22 can be varied by actuating piezoelectric coils 128 and 130. By continually varying the optical path lengths, the tissue depth can be 15 scanned such that the intensity of light scattering from a series of specific depths can be measured. For example, when the: optical path length of B, is 0.5 mm longer than the optical path length of B2, the intensity of light scattered from an optically equivalent (adjusted for the change in group refractive indices) depth of 0.5 mm in the tissue is measured. The optical path lengths are continually varied, and intensity of scattered light measured to develop a function of scattering intensity versus distance. Thus, the interferometric technique precisely measures very small distances and thicknesses, so that a high resolution image of tissue T can be formed, providing on-line, high resolution information to determine if ablative device 140 can be safely enabled or advanced. Further details an the interferometric technique and interferometric apparatus are described in co-pending U.S. Patent Application Serial Nos. 09/060,487 (filed April 15, 1998), which is assigned to the present assignee, and which is incorporated herein, in its entirety, by ref<;rence. In alternate embodiments, in place of interferometric apparatus 106, control system 100 is instead coupled to an apparatus which uses a different technique for analyzing reflected light, such as Roman or Rayleigh spectroscopy, induced fluorescence, or other linear or non linear techniques. For example, when coupled to a spectroscopic apparatus, microprocessor 102 uses analysis of spectroscopic data to identify an interface 5 between abnormal and normal tissue.
Figure 3 is a graph showing the scai:tering effects on light beam B~ of an abnormal tissue: an area of plaque 302 in a diseased artery. The graph shows intensity of reflected light in decibels as a function of distance from distal end 126 of second optical fiber 122. On such a graph, plaque area 302 is I0 distinguishable from an area 304 of normal, healthy artery tissue by an increased and steady decay of reflected light intensity as a function of distance. More specifically, by determining the slope of the decay, abnormal tissue is identified as described below in more detail. The steady decay exhibited in area 302 relative to area 304 is attributable to the relatively unorganized structure of 15 abnormal tissue, in this case plaque, which tends to scatter light in randorn directions, thereby decreasing the intensity of reflected light transmitted back through second optical fiber 122. The relatively more organized structure of normal tissue, in this case healthy arterial wail, scatters the light in a birefringent or anisotropic pattern so that relatively nnore light is reflected back through 20 second optical fiber 122.
Microprocessor 102 supplies control signals to energy controller 104.
More specifically, the control algorithm detects the presence of abnormal tissue by examining the rate of decay of reflected light intensity as a function of distance from distal end I26 of second optical fiber 122. For example, microprocessor 25 102. samples the reflected light at about 10 hertz, and generates a sliding average of multiple points, for example averaging the intensity value over a window of about 8 to about 30 points at a time. The sliding average identifies inflection points in the function which represent a true or actual change in the slope of the function, as opposed to noise. An actual change in slope identifies an interface WO 00/41611 PCT/US00l00460 between normal tissue and abnormal tissue. For example, using a light source of about 100 microWatts, emitting light at a wavelength of 1300 nm, normal tissue is identified by regions of the function having a slope of less than about -75 dB/mm. Regions of the function having; a slope within the range of about -5 dBlmm to about -I50 dBlmm indicate a soft plaque such as a fatty or lipid plaque. A slope within about -150 dB/mm to about -200 dB/mm would indicate a calcified plaque, while a slope greater than about -200 dB/mm indicates air or blood. The algorithm is, for example, a simple go/no-go algorithm in which the inflection points between regions of the function having different slopes are used 10 to determine the state of control signals supplied to energy controller I04 to either enable or disenable tissue ablative device 140. In alternative embodiments, the algorithm can be configured to perform a more complex pattern recognition or noise analysis which identifies the chang<a in reflected light which characterize the interfaces between normal and abnormal tissue.
15 Far example, Figure 3 shows reflected light intensity as a function of distance in an artery, using a light source of about 100 microWatts emitting light at a wavelength of 1300 nm. From aboul: 0.100 mm to about 0.200 mm from distal end I26 of second optical Fiber 122 ., the slope of the function is less than about -75 dBlmm, which indicates normal, healthy tissue in area 304. At 20 approximately 0.200 mm from distal end 126, the slope of the function changes, which microprocessor 102 identifies as an interface between normal tissue (arterial wall) and abnormal tissue, in this case a plaque. The slope of the function from about 0.200 mm to about 0.:?75 mm, plaque area 302, from distal end 126 is about -I00 dBlmm. This slope falls within the range of about -75 25 dB/mm to about -150 dB/mm, which indicates a soft plaque such as a fatty or lipid plague. At about 0.275 mm from distal end I26, the slope of the function again changes, and microprocessor 102 idf;ntifies an interface. In this case, the slope of the function from about 0.275 mrn to about 0.350 mm from distal end 126 is about -267 dB/rnm, indicating air or blood, so that microprocessor I02 identifies an interface between the end of a plaque and air or blood at 0.275 mm from distal end 126. A change in slope representing a decrease in decay of reflected light as a function of distance (i.e. a decrease in slope), not shown, would identify an interface between the end of a plaque and normal tissue.
5 Figure 4 shows the intensity of reflected light as a function of distance in a normal, healthy artery, using a light source of about 100 microWatts emitting light at a wavelength of 1300 nm. The function from about 0.100 mm to about 0.230 mm from distal end 126 has a slope c~f about -70 dBlmm, indicating normal tissue. At about 0.230 mm, the slope of the function from about 0.230 mm to 10 about 0.290 mm increases to about -400 db/mm, indicating blood in the artery.
In typical use, for example, distal end 144 of disenabled tissue ablative element 140 is positioned within a normal section of artery and advanced along a longitudinal axis of the artery defined by the length of second optical fiber 122.
The start of an area or region of abnormal tissue, such as an atherosclerotic I S plaque, is identified when microprocessor 102 identifies a normal tissue/abnormal tissue interface ahead of second optic fiber distal end 126 (and distal end 144 of tissue ablative element 140). Tissue ablatiive element distal end 144 is advanced just past the interface, e.g., the start of the plaque, and then microprocessor 102 supplies signals to energy controller 104 to activate energy source 138 so that 20 tissue ablative device 140 is enabled and the abnormal tissue (plaque) is ablated.
In one embodiment, to insure that normal tissue is not inadvertently damaged, a small area or region of plaque behind the area where ablative element 140 is first enabled can be left remaining. Tissue ablative element 140 is advanced through the plaque, and can be safely enabled as long as no tissue interface between the 25 abnormal tissue (plaque) and narmal tissue is detected by microprocessor 102.
In one embodiment, when microprocessor 102, using the output of interferometric apparatus 106, identifies an interface between the abnormal (plaque) tissue and normal tissue ahead of second optic fiber distal end 126, microprocessor 102 accordingly supplies signals to energy controller 104 to WO fl0/41611 PCT/US00/fl0460 _12_ deactivate energy source 138 so that tissuf: ablative element 140 is disenabled before reaching the normal tissue, and normal tissue is undamaged by tissue ablative element 140. A small area or region of plaque at the end of the plaque relative to tissue ablative element distal end 144 may be left remaining, to insure 5 that normal tissue is undamaged by tissue ablative element 140. However, it should be recognized by those skilled in the art that the relative position of tissue ablative element 140 with respect to an atrnormal/normal or normal/abnormal tissue interface, at which tissue ablative element 140 is enabled or disenabled, can be varied. Further, the amount of energy delivered to tissue ablative element 10 can be adjusted depending on whether a soft plaque or calcified plaque has been identified. For example, if a calcified plaque is identified, a lower amount of energy can first be delivered to tissue ablative element 140. If the plaque is not ablated using a lower amount of energy, then the energy can be upwardly adjusted to ablate the calcified plaque.
15 In an exemplary embodiment, control system 100 performs real-time control of tissue ablation without further input from an operator. In an alternative embodiment, control system 100 is further linked to a stepping motor or the like, which is linked to tissue ablative element 140 and to microprocessor 102. The stepping motor responds to control signals from microprocessor 102 20 by advancing or retracting tissue ablative element 140 so that both enablement and advancement of tissue ablative element 140 are automatically controlled by control system 100. For example, after abnormal tissue has been detected and tissue ablative element 140 enabled, tissue ablative element 140 is advanced as long as a tissue interface between the abnormal tissue and normal tissue is not 25 detected. Tissue ablative element 140 continues to advance until such a tissue interface is identified, indicating normal tissue ahead of tissue ablative element 140. Once such an interface is identified, tissue ablative element 140 is disenabled and can be retracted. In an alternative method of use, a manual operator of tissue ablative element 140 many view the pseudoimage on output display device 136 for real-time imaging of the tissue so that the operator can accordingly respond by manually activating or deactivating the energy controller, or by manually advancing or retracting ablative element 140. Because second optical fiber 122 can be used simultaneously and side-by-side with tissue ablative element 140, the system can provide continuous, high resolution imaging.data to the operator as tissue ablative element 140 is advanced.
The control system thus provides high resolution imaging data for automated or manual control of minimally invasive tissue ablative devices. In an alternative embodiment, a variety of tissue ablative modalities, devices and probes, including radio frequency devices, microwave devices, ultrasound devices, mechanical cutting or atherectomy devices and laser catheters, as known in the art, are used with control system 100. Further, the guidance system can be used simultaneously with the tissue ablative element to provide continuous online information regarding the tissue being treated, as the tissue ablative element is being advanced.
From the preceding description of various embodiments of the present invention, it is evident that the objects of the invention are attained.
Although the invention has been described and illustrated in detail, it is to be clearly understood that the same is intended by way of illustration and example only and is not to be taken by way of limitation. Accordingly, the spirit and scope of the invention are to be limited only by the terms of the appended claims.
Claims (22)
1. A control system for controlling a tissue ablative apparatus, said control system comprising a microprocessor and an energy controller, said system coupled to the tissue ablative apparatus and configured to:
detect whether an interface between an abnormal tissue and a normal tissue is present;
if the interface is present, alter the operation of the tissue ablative apparatus.
detect whether an interface between an abnormal tissue and a normal tissue is present;
if the interface is present, alter the operation of the tissue ablative apparatus.
2. A system in accordance with Claim 1 wherein an interferometric apparatus configured to generate interference data is coupled to said control system, and wherein to detect whether an interface is present, said system is configured to:
identify an interface between abnormal tissue and normal tissue using the interference data.
identify an interface between abnormal tissue and normal tissue using the interference data.
3. A system in accordance with Claim 2 wherein the interferometric apparatus includes a sampling optical fiber having a distal sampling end, and wherein to detect whether an interface between normal tissue and abnormal tissue is present, said system is configured to:
generate a function for reflected light intensity against distance from the sampling end of the sampling optical fiber utilizing the interference data;
and determine a rate of decay of the function.
generate a function for reflected light intensity against distance from the sampling end of the sampling optical fiber utilizing the interference data;
and determine a rate of decay of the function.
4. A system in accordance with Claim 3 wherein to determine the rate of decay of the function, said system is configured to identify actual inflection points of the function.
5. A system in accordance with Claim 2 further configured to generate a psuedoimage of a tissue utilizing the interference data.
6. A system in accordance with Claim 1 wherein a spectroscopic apparatus configured to generate spectroscopic data is coupled to said control system, and wherein to detect whether an interface is present, said system is configured to:
identify an interface between abnormal tissue and normal tissue using the spectroscopic data.
identify an interface between abnormal tissue and normal tissue using the spectroscopic data.
7. A system in accordance with Claim 6 wherein the spectroscopic apparatus comprises Raman spectroscopic apparatus.
8. A system in accordance with Claim 6 wherein the spectroscopic apparatus comprises Rayleigh spectroscopic apparatus.
9. A system in accordance with Claim 1 wherein to alter the operation of the tissue ablative apparatus, said system is configured to enable the tissue ablative apparatus to ablate the abnormal tissue, if an interface between normal and abnormal tissue is detected.
10. A system in accordance with Claim 1 wherein to alter the operation of the tissue ablative apparatus, said system is configured to disenable the tissue ablative apparatus so that the normal tissue is unharmed, if an interface between abnormal and normal tissue is detected.
11. A system in accordance with Claim 1 wherein the tissue ablative apparatus includes a tissue ablative element coupled to an energy source, the energy source coupled to said control system, and wherein to alter the operation of the ablative apparatus, said system is configured to alter control signals supplied to the energy source.
12. A system in accordance with Claim 1 wherein the tissue ablative apparatus includes a stepping motor, and wherein to alter the operation of the tissue ablative apparatus, said system configured to alter control signals supplied to the stepping motor.
13. A tissue ablation system for ablating tissue, said system comprising:
tissue ablative apparatus comprising a tissue ablative element and an ablation energy source interferometric apparatus comprising a low coherence light source, for providing interference data; and a control system coupled to said interferometric apparatus, said control system comprising a microprocessor and an energy controller coupled to said ablation energy source for altering an energy signal supplied to said tissue ablative apparatus, said control system configured to use the interference data to detect whether an interface between normal tissue and abnormal tissue is present and if the interface is present, alter the energy signal supplied to the tissue ablative apparatus.
tissue ablative apparatus comprising a tissue ablative element and an ablation energy source interferometric apparatus comprising a low coherence light source, for providing interference data; and a control system coupled to said interferometric apparatus, said control system comprising a microprocessor and an energy controller coupled to said ablation energy source for altering an energy signal supplied to said tissue ablative apparatus, said control system configured to use the interference data to detect whether an interface between normal tissue and abnormal tissue is present and if the interface is present, alter the energy signal supplied to the tissue ablative apparatus.
14. A system in accordance with Claim 13, wherein to alter the operation of the tissue ablative apparatus, said system configured to:
detect whether an interface between normal tissue and abnormal tissue is present; and if the interface is present, alter the operation of the tissue ablative apparatus.
detect whether an interface between normal tissue and abnormal tissue is present; and if the interface is present, alter the operation of the tissue ablative apparatus.
15. A system in accordance with Claim 13 wherein said tissue ablative apparatus comprises:
a tissue ablative element; and an energy source coupled to said energy controller and to said tissue ablative element.
a tissue ablative element; and an energy source coupled to said energy controller and to said tissue ablative element.
16. A system in accordance with Claim 15 wherein said tissue ablative element comprises a laser catheter.
17. A system in accordance with Claim 15 wherein said tissue ablative element comprises a radio frequency device.
18. A system in accordance with Claim 15 wherein said tissue ablative element comprises a mechanical atherectomy device.
19. A system in accordance with Claim 15 wherein said tissue ablative element comprises an ultrasound device.
20. A system in accordance with Claim 15 wherein said tissue ablative element comprises a microwave device.
21. A system in accordance with Claim 15 further comprising an output display device coupled to said microprocessor.
22. A system in accordance with Claim 15 wherein said output display device comprises a computer monitor.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/228,030 | 1999-01-09 | ||
| US09/228,030 US6228076B1 (en) | 1999-01-09 | 1999-01-09 | System and method for controlling tissue ablation |
| PCT/US2000/000460 WO2000041611A2 (en) | 1999-01-09 | 2000-01-07 | System and method for controlling tissue ablation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2355835A1 true CA2355835A1 (en) | 2000-07-20 |
Family
ID=22855463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002355835A Abandoned CA2355835A1 (en) | 1999-01-09 | 2000-01-07 | System and method for controlling tissue ablation |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6228076B1 (en) |
| EP (1) | EP1146930B1 (en) |
| JP (1) | JP4226788B2 (en) |
| KR (1) | KR100623212B1 (en) |
| AT (1) | ATE548078T1 (en) |
| AU (1) | AU769737B2 (en) |
| BR (1) | BR0007419A (en) |
| CA (1) | CA2355835A1 (en) |
| HK (1) | HK1040648A1 (en) |
| IL (1) | IL144183A (en) |
| WO (1) | WO2000041611A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107727636A (en) * | 2017-10-13 | 2018-02-23 | 中国科学院上海技术物理研究所 | It is a kind of that serum analysis method is frozen based on the ultraviolet Raman fluorescence Spectra of time domain resolution |
Families Citing this family (217)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6575964B1 (en) | 1998-02-03 | 2003-06-10 | Sciton, Inc. | Selective aperture for laser delivery system for providing incision, tissue ablation and coagulation |
| US6235044B1 (en) * | 1999-08-04 | 2001-05-22 | Scimed Life Systems, Inc. | Percutaneous catheter and guidewire for filtering during ablation of mycardial or vascular tissue |
| US7708749B2 (en) | 2000-12-20 | 2010-05-04 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
| US8328829B2 (en) | 1999-08-19 | 2012-12-11 | Covidien Lp | High capacity debulking catheter with razor edge cutting window |
| US7713279B2 (en) | 2000-12-20 | 2010-05-11 | Fox Hollow Technologies, Inc. | Method and devices for cutting tissue |
| US20030120295A1 (en) * | 2000-12-20 | 2003-06-26 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
| US6638233B2 (en) | 1999-08-19 | 2003-10-28 | Fox Hollow Technologies, Inc. | Apparatus and methods for material capture and removal |
| US7887556B2 (en) * | 2000-12-20 | 2011-02-15 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
| US6299622B1 (en) | 1999-08-19 | 2001-10-09 | Fox Hollow Technologies, Inc. | Atherectomy catheter with aligned imager |
| US20030125757A1 (en) * | 2000-12-20 | 2003-07-03 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
| EP1090582B1 (en) * | 1999-10-01 | 2001-05-23 | Karl Storz GmbH & Co. KG | Imaging method for determining condition of tissue |
| US6451009B1 (en) * | 2000-09-12 | 2002-09-17 | The Regents Of The University Of California | OCDR guided laser ablation device |
| US20100121360A9 (en) * | 2000-12-20 | 2010-05-13 | Fox Hollow Technologies, Inc | Testing a patient population having a cardiovascular condition for drug efficacy |
| US20050154407A1 (en) * | 2000-12-20 | 2005-07-14 | Fox Hollow Technologies, Inc. | Method of evaluating drug efficacy for treating atherosclerosis |
| US20060235366A1 (en) * | 2000-12-20 | 2006-10-19 | Fox Hollow Technologies, Inc. | Method of evaluating a treatment for vascular disease |
| US7699790B2 (en) * | 2000-12-20 | 2010-04-20 | Ev3, Inc. | Debulking catheters and methods |
| US7927784B2 (en) * | 2000-12-20 | 2011-04-19 | Ev3 | Vascular lumen debulking catheters and methods |
| ATE499054T1 (en) | 2000-12-20 | 2011-03-15 | Fox Hollow Technologies Inc | REDUCTION CATHETER |
| US20040167554A1 (en) * | 2000-12-20 | 2004-08-26 | Fox Hollow Technologies, Inc. | Methods and devices for reentering a true lumen from a subintimal space |
| US6743221B1 (en) * | 2001-03-13 | 2004-06-01 | James L. Hobart | Laser system and method for treatment of biological tissues |
| WO2002083003A1 (en) * | 2001-04-11 | 2002-10-24 | Clarke Dana S | Tissue structure identification in advance of instrument |
| US6770069B1 (en) | 2001-06-22 | 2004-08-03 | Sciton, Inc. | Laser applicator |
| US20040015159A1 (en) * | 2001-07-03 | 2004-01-22 | Syntheon, Llc | Methods and apparatus for treating the wall of a blood vessel with electromagnetic energy |
| US7734332B2 (en) * | 2002-10-18 | 2010-06-08 | Ariomedica Ltd. | Atherectomy system with imaging guidewire |
| HUP0203993A2 (en) * | 2002-11-19 | 2004-08-30 | László Domján | Optical system of binocular video glass |
| US8092450B2 (en) * | 2003-01-21 | 2012-01-10 | Baylis Medical Company Inc. | Magnetically guidable energy delivery apparatus and method of using same |
| EP2319405B1 (en) * | 2003-01-24 | 2013-09-18 | The General Hospital Corporation | System and method for identifying tissue using low-coherence interferometry |
| US8246640B2 (en) | 2003-04-22 | 2012-08-21 | Tyco Healthcare Group Lp | Methods and devices for cutting tissue at a vascular location |
| AU2004285412A1 (en) * | 2003-09-12 | 2005-05-12 | Minnow Medical, Llc | Selectable eccentric remodeling and/or ablation of atherosclerotic material |
| US20050171437A1 (en) * | 2004-01-14 | 2005-08-04 | Neptec Optical Solutions, Inc. | Optical switching system for catheter-based analysis and treatment |
| US20050250091A1 (en) * | 2004-05-05 | 2005-11-10 | Chemlmage Corporation | Raman molecular imaging for detection of bladder cancer |
| US20050251116A1 (en) * | 2004-05-05 | 2005-11-10 | Minnow Medical, Llc | Imaging and eccentric atherosclerotic material laser remodeling and/or ablation catheter |
| US7742795B2 (en) * | 2005-03-28 | 2010-06-22 | Minnow Medical, Inc. | Tuned RF energy for selective treatment of atheroma and other target tissues and/or structures |
| US8396548B2 (en) | 2008-11-14 | 2013-03-12 | Vessix Vascular, Inc. | Selective drug delivery in a lumen |
| US9277955B2 (en) | 2010-04-09 | 2016-03-08 | Vessix Vascular, Inc. | Power generating and control apparatus for the treatment of tissue |
| US9713730B2 (en) | 2004-09-10 | 2017-07-25 | Boston Scientific Scimed, Inc. | Apparatus and method for treatment of in-stent restenosis |
| US7794413B2 (en) * | 2005-04-19 | 2010-09-14 | Ev3, Inc. | Libraries and data structures of materials removed by debulking catheters |
| US20070038173A1 (en) * | 2005-07-27 | 2007-02-15 | Fox Hollow Technologies, Inc. | Methods affecting markers in patients having vascular disease |
| US7989207B2 (en) * | 2006-02-17 | 2011-08-02 | Tyco Healthcare Group Lp | Testing lumenectomy samples for markers of non-vascular diseases |
| US8019435B2 (en) | 2006-05-02 | 2011-09-13 | Boston Scientific Scimed, Inc. | Control of arterial smooth muscle tone |
| US20070276419A1 (en) | 2006-05-26 | 2007-11-29 | Fox Hollow Technologies, Inc. | Methods and devices for rotating an active element and an energy emitter on a catheter |
| US20080058789A1 (en) * | 2006-09-06 | 2008-03-06 | Cardiofirst | Guidance system used in treating chronic occlusion |
| US20100049180A1 (en) * | 2007-10-19 | 2010-02-25 | Lockheed Martin Corporation | System and method for conditioning animal tissue using laser light |
| US11666377B2 (en) | 2006-09-29 | 2023-06-06 | Boston Scientific Medical Device Limited | Electrosurgical device |
| US20210121227A1 (en) | 2006-09-29 | 2021-04-29 | Baylis Medical Company Inc. | Connector system for electrosurgical device |
| CA2666661C (en) | 2006-10-18 | 2015-01-20 | Minnow Medical, Inc. | Tuned rf energy and electrical tissue characterization for selective treatment of target tissues |
| JP5479901B2 (en) * | 2006-10-18 | 2014-04-23 | べシックス・バスキュラー・インコーポレイテッド | Induction of desired temperature effects on body tissue |
| EP2455034B1 (en) * | 2006-10-18 | 2017-07-19 | Vessix Vascular, Inc. | System for inducing desirable temperature effects on body tissue |
| US9028520B2 (en) | 2006-12-22 | 2015-05-12 | The Spectranetics Corporation | Tissue separating systems and methods |
| US8961551B2 (en) | 2006-12-22 | 2015-02-24 | The Spectranetics Corporation | Retractable separating systems and methods |
| US8202268B1 (en) | 2007-03-18 | 2012-06-19 | Lockheed Martin Corporation | Method and multiple-mode device for high-power short-pulse laser ablation and CW cauterization of bodily tissues |
| US8496653B2 (en) | 2007-04-23 | 2013-07-30 | Boston Scientific Scimed, Inc. | Thrombus removal |
| WO2009005850A1 (en) * | 2007-06-29 | 2009-01-08 | Tyco Healthcare Group, Lp | Method and system for monitoring tissue during an electrosurgical procedure |
| US8784440B2 (en) | 2008-02-25 | 2014-07-22 | Covidien Lp | Methods and devices for cutting tissue |
| US9125562B2 (en) | 2009-07-01 | 2015-09-08 | Avinger, Inc. | Catheter-based off-axis optical coherence tomography imaging system |
| US8062316B2 (en) | 2008-04-23 | 2011-11-22 | Avinger, Inc. | Catheter system and method for boring through blocked vascular passages |
| US8548571B2 (en) | 2009-12-08 | 2013-10-01 | Avinger, Inc. | Devices and methods for predicting and preventing restenosis |
| US8133222B2 (en) | 2008-05-28 | 2012-03-13 | Medwaves, Inc. | Tissue ablation apparatus and method using ultrasonic imaging |
| EP2293714B1 (en) | 2008-06-02 | 2014-08-13 | Lightlab Imaging, Inc. | Quantitative methods for obtaining tissue characteristics from optical coherence tomography images |
| KR101645754B1 (en) | 2008-10-13 | 2016-08-04 | 코비디엔 엘피 | Devices and methods for manipulating a catheter shaft |
| CN102271603A (en) * | 2008-11-17 | 2011-12-07 | 明诺医学股份有限公司 | Selective accumulation of energy with or without knowledge of tissue topography |
| WO2010129075A1 (en) | 2009-04-28 | 2010-11-11 | Avinger, Inc. | Guidewire support catheter |
| CN102625673B (en) | 2009-04-29 | 2014-12-24 | 泰科保健集团有限合伙公司 | Methods and devices for cutting and abrading tissue |
| US8551096B2 (en) | 2009-05-13 | 2013-10-08 | Boston Scientific Scimed, Inc. | Directional delivery of energy and bioactives |
| AU2010248909B2 (en) | 2009-05-14 | 2013-03-21 | Covidien Lp | Easily cleaned atherectomy catheters and methods of use |
| CA2763324C (en) | 2009-05-28 | 2018-10-23 | Avinger, Inc. | Optical coherence tomography for biological imaging |
| EP2448502B1 (en) * | 2009-07-01 | 2022-04-06 | Avinger, Inc. | Atherectomy catheter with laterally-displaceable tip |
| AU2010326063B2 (en) | 2009-12-02 | 2013-07-04 | Covidien Lp | Methods and devices for cutting tissue |
| JP5511107B2 (en) | 2009-12-11 | 2014-06-04 | コヴィディエン リミテッド パートナーシップ | Substance removal device and method with improved substance capture efficiency |
| US9192790B2 (en) | 2010-04-14 | 2015-11-24 | Boston Scientific Scimed, Inc. | Focused ultrasonic renal denervation |
| US8473067B2 (en) | 2010-06-11 | 2013-06-25 | Boston Scientific Scimed, Inc. | Renal denervation and stimulation employing wireless vascular energy transfer arrangement |
| US9119662B2 (en) | 2010-06-14 | 2015-09-01 | Covidien Lp | Material removal device and method of use |
| WO2014039096A1 (en) | 2012-09-06 | 2014-03-13 | Avinger, Inc. | Re-entry stylet for catheter |
| WO2014039099A1 (en) | 2012-09-06 | 2014-03-13 | Avinger, Inc. | Balloon atherectomy catheters with imaging |
| JP2013531542A (en) | 2010-07-01 | 2013-08-08 | アビンガー・インコーポレイテッド | An atherectomy catheter having a longitudinally movable drive shaft |
| US11382653B2 (en) | 2010-07-01 | 2022-07-12 | Avinger, Inc. | Atherectomy catheter |
| JP2013532519A (en) * | 2010-07-20 | 2013-08-19 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Motion compensated surgical instrument system and surgical instrument |
| US9155589B2 (en) | 2010-07-30 | 2015-10-13 | Boston Scientific Scimed, Inc. | Sequential activation RF electrode set for renal nerve ablation |
| US9358365B2 (en) | 2010-07-30 | 2016-06-07 | Boston Scientific Scimed, Inc. | Precision electrode movement control for renal nerve ablation |
| US9408661B2 (en) | 2010-07-30 | 2016-08-09 | Patrick A. Haverkost | RF electrodes on multiple flexible wires for renal nerve ablation |
| US9463062B2 (en) | 2010-07-30 | 2016-10-11 | Boston Scientific Scimed, Inc. | Cooled conductive balloon RF catheter for renal nerve ablation |
| US9084609B2 (en) | 2010-07-30 | 2015-07-21 | Boston Scientific Scime, Inc. | Spiral balloon catheter for renal nerve ablation |
| JP2012135475A (en) * | 2010-12-27 | 2012-07-19 | Fujifilm Corp | Diagnosis support apparatus, diagnosis support method, lesioned part detection apparatus, and lesioned part detection method |
| JP2012137405A (en) * | 2010-12-27 | 2012-07-19 | Fujifilm Corp | Diagnosis support device and method, and device and method for detecting lesion part |
| US8974451B2 (en) | 2010-10-25 | 2015-03-10 | Boston Scientific Scimed, Inc. | Renal nerve ablation using conductive fluid jet and RF energy |
| US9220558B2 (en) | 2010-10-27 | 2015-12-29 | Boston Scientific Scimed, Inc. | RF renal denervation catheter with multiple independent electrodes |
| CA2815186C (en) | 2010-10-28 | 2015-12-29 | Covidien Lp | Material removal device and method of use |
| AU2011326420B2 (en) | 2010-11-11 | 2014-11-27 | Covidien Lp | Flexible debulking catheters with imaging and methods of use and manufacture |
| US9028485B2 (en) | 2010-11-15 | 2015-05-12 | Boston Scientific Scimed, Inc. | Self-expanding cooling electrode for renal nerve ablation |
| US9668811B2 (en) | 2010-11-16 | 2017-06-06 | Boston Scientific Scimed, Inc. | Minimally invasive access for renal nerve ablation |
| US9089350B2 (en) | 2010-11-16 | 2015-07-28 | Boston Scientific Scimed, Inc. | Renal denervation catheter with RF electrode and integral contrast dye injection arrangement |
| US9326751B2 (en) | 2010-11-17 | 2016-05-03 | Boston Scientific Scimed, Inc. | Catheter guidance of external energy for renal denervation |
| US9060761B2 (en) | 2010-11-18 | 2015-06-23 | Boston Scientific Scime, Inc. | Catheter-focused magnetic field induced renal nerve ablation |
| US9023034B2 (en) | 2010-11-22 | 2015-05-05 | Boston Scientific Scimed, Inc. | Renal ablation electrode with force-activatable conduction apparatus |
| US9192435B2 (en) | 2010-11-22 | 2015-11-24 | Boston Scientific Scimed, Inc. | Renal denervation catheter with cooled RF electrode |
| US20120157993A1 (en) | 2010-12-15 | 2012-06-21 | Jenson Mark L | Bipolar Off-Wall Electrode Device for Renal Nerve Ablation |
| US9220561B2 (en) | 2011-01-19 | 2015-12-29 | Boston Scientific Scimed, Inc. | Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury |
| JP6063875B2 (en) | 2011-02-24 | 2017-01-18 | エキシモ メディカル リミテッド | Hybrid catheter for tissue resection |
| US9949754B2 (en) | 2011-03-28 | 2018-04-24 | Avinger, Inc. | Occlusion-crossing devices |
| WO2012145133A2 (en) | 2011-03-28 | 2012-10-26 | Avinger, Inc. | Occlusion-crossing devices, imaging, and atherectomy devices |
| AU2012283908B2 (en) | 2011-07-20 | 2017-02-16 | Boston Scientific Scimed, Inc. | Percutaneous devices and methods to visualize, target and ablate nerves |
| WO2013016203A1 (en) | 2011-07-22 | 2013-01-31 | Boston Scientific Scimed, Inc. | Nerve modulation system with a nerve modulation element positionable in a helical guide |
| US8992717B2 (en) | 2011-09-01 | 2015-03-31 | Covidien Lp | Catheter with helical drive shaft and methods of manufacture |
| EP2765942B1 (en) | 2011-10-10 | 2016-02-24 | Boston Scientific Scimed, Inc. | Medical devices including ablation electrodes |
| US9420955B2 (en) | 2011-10-11 | 2016-08-23 | Boston Scientific Scimed, Inc. | Intravascular temperature monitoring system and method |
| US10085799B2 (en) | 2011-10-11 | 2018-10-02 | Boston Scientific Scimed, Inc. | Off-wall electrode device and methods for nerve modulation |
| US9364284B2 (en) | 2011-10-12 | 2016-06-14 | Boston Scientific Scimed, Inc. | Method of making an off-wall spacer cage |
| WO2013059363A1 (en) | 2011-10-17 | 2013-04-25 | Avinger, Inc. | Atherectomy catheters and non-contact actuation mechanism for catheters |
| US9079000B2 (en) | 2011-10-18 | 2015-07-14 | Boston Scientific Scimed, Inc. | Integrated crossing balloon catheter |
| EP2768563B1 (en) | 2011-10-18 | 2016-11-09 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
| EP2775948B1 (en) | 2011-11-08 | 2018-04-04 | Boston Scientific Scimed, Inc. | Ostial renal nerve ablation |
| US9345406B2 (en) | 2011-11-11 | 2016-05-24 | Avinger, Inc. | Occlusion-crossing devices, atherectomy devices, and imaging |
| EP2779929A1 (en) | 2011-11-15 | 2014-09-24 | Boston Scientific Scimed, Inc. | Device and methods for renal nerve modulation monitoring |
| US9119632B2 (en) | 2011-11-21 | 2015-09-01 | Boston Scientific Scimed, Inc. | Deflectable renal nerve ablation catheter |
| US9265969B2 (en) | 2011-12-21 | 2016-02-23 | Cardiac Pacemakers, Inc. | Methods for modulating cell function |
| WO2013096913A2 (en) | 2011-12-23 | 2013-06-27 | Vessix Vascular, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
| WO2013101452A1 (en) | 2011-12-28 | 2013-07-04 | Boston Scientific Scimed, Inc. | Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements |
| US9050106B2 (en) | 2011-12-29 | 2015-06-09 | Boston Scientific Scimed, Inc. | Off-wall electrode device and methods for nerve modulation |
| US10660703B2 (en) | 2012-05-08 | 2020-05-26 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices |
| EP2849636B1 (en) | 2012-05-14 | 2020-04-22 | Avinger, Inc. | Optical coherence tomography with graded index fiber for biological imaging |
| EP2849660B1 (en) | 2012-05-14 | 2021-08-25 | Avinger, Inc. | Atherectomy catheter drive assemblies |
| EP2849661B1 (en) | 2012-05-14 | 2020-12-09 | Avinger, Inc. | Atherectomy catheters with imaging |
| JP6416084B2 (en) | 2012-05-31 | 2018-10-31 | ベイリス メディカル カンパニー インコーポレイテッドＢａｙｌｉｓ Ｍｅｄｉｃａｌ Ｃｏｍｐａｎｙ Ｉｎｃ． | Medical equipment |
| US10321946B2 (en) | 2012-08-24 | 2019-06-18 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices with weeping RF ablation balloons |
| JP6654897B2 (en) | 2012-08-31 | 2020-02-26 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | Particles, methods and uses thereof |
| US11284916B2 (en) | 2012-09-06 | 2022-03-29 | Avinger, Inc. | Atherectomy catheters and occlusion crossing devices |
| US9498247B2 (en) | 2014-02-06 | 2016-11-22 | Avinger, Inc. | Atherectomy catheters and occlusion crossing devices |
| US9579157B2 (en) | 2012-09-13 | 2017-02-28 | Covidien Lp | Cleaning device for medical instrument and method of use |
| US9763692B2 (en) | 2012-09-14 | 2017-09-19 | The Spectranetics Corporation | Tissue slitting methods and systems |
| EP2895095A2 (en) | 2012-09-17 | 2015-07-22 | Boston Scientific Scimed, Inc. | Self-positioning electrode system and method for renal nerve modulation |
| US10549127B2 (en) | 2012-09-21 | 2020-02-04 | Boston Scientific Scimed, Inc. | Self-cooling ultrasound ablation catheter |
| US10398464B2 (en) | 2012-09-21 | 2019-09-03 | Boston Scientific Scimed, Inc. | System for nerve modulation and innocuous thermal gradient nerve block |
| JP6074051B2 (en) | 2012-10-10 | 2017-02-01 | ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． | Intravascular neuromodulation system and medical device |
| US9943329B2 (en) | 2012-11-08 | 2018-04-17 | Covidien Lp | Tissue-removing catheter with rotatable cutter |
| CA2894719C (en) | 2012-12-19 | 2019-10-22 | Sloan-Kettering Institute For Cancer Research | Multimodal particles, methods and uses thereof |
| CA2900686A1 (en) * | 2013-02-20 | 2014-08-28 | Sloan-Kettering Institute For Cancer Research | Wide field raman imaging apparatus and associated methods |
| WO2014143571A1 (en) | 2013-03-11 | 2014-09-18 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
| US9956033B2 (en) | 2013-03-11 | 2018-05-01 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
| US11937873B2 (en) | 2013-03-12 | 2024-03-26 | Boston Scientific Medical Device Limited | Electrosurgical device having a lumen |
| US9456872B2 (en) | 2013-03-13 | 2016-10-04 | The Spectranetics Corporation | Laser ablation catheter |
| US9808311B2 (en) | 2013-03-13 | 2017-11-07 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
| US9291663B2 (en) | 2013-03-13 | 2016-03-22 | The Spectranetics Corporation | Alarm for lead insulation abnormality |
| US9883885B2 (en) | 2013-03-13 | 2018-02-06 | The Spectranetics Corporation | System and method of ablative cutting and pulsed vacuum aspiration |
| US10383691B2 (en) | 2013-03-13 | 2019-08-20 | The Spectranetics Corporation | Last catheter with helical internal lumen |
| US9283040B2 (en) | 2013-03-13 | 2016-03-15 | The Spectranetics Corporation | Device and method of ablative cutting with helical tip |
| US10835279B2 (en) | 2013-03-14 | 2020-11-17 | Spectranetics Llc | Distal end supported tissue slitting apparatus |
| US9668765B2 (en) | 2013-03-15 | 2017-06-06 | The Spectranetics Corporation | Retractable blade for lead removal device |
| US9918737B2 (en) | 2013-03-15 | 2018-03-20 | The Spectranetics Corporation | Medical device for removing an implanted object |
| US9980743B2 (en) | 2013-03-15 | 2018-05-29 | The Spectranetics Corporation | Medical device for removing an implanted object using laser cut hypotubes |
| WO2014143064A1 (en) | 2013-03-15 | 2014-09-18 | Avinger, Inc. | Chronic total occlusion crossing devices with imaging |
| US10932670B2 (en) | 2013-03-15 | 2021-03-02 | Avinger, Inc. | Optical pressure sensor assembly |
| US10842532B2 (en) | 2013-03-15 | 2020-11-24 | Spectranetics Llc | Medical device for removing an implanted object |
| US10265122B2 (en) | 2013-03-15 | 2019-04-23 | Boston Scientific Scimed, Inc. | Nerve ablation devices and related methods of use |
| CN105228546B (en) | 2013-03-15 | 2017-11-14 | 波士顿科学国际有限公司 | Utilize the impedance-compensated medicine equipment and method that are used to treat hypertension |
| US11096717B2 (en) | 2013-03-15 | 2021-08-24 | Avinger, Inc. | Tissue collection device for catheter |
| US10448999B2 (en) | 2013-03-15 | 2019-10-22 | The Spectranetics Corporation | Surgical instrument for removing an implanted object |
| EP2967634B1 (en) | 2013-03-15 | 2019-06-05 | The Spectranetics Corporation | Surgical instrument for removing an implanted object |
| JP6220044B2 (en) | 2013-03-15 | 2017-10-25 | ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． | Medical device for renal nerve ablation |
| AU2014233354B2 (en) | 2013-03-15 | 2017-01-12 | Medtronic Af Luxembourg S.A.R.L. | Controlled neuromodulation systems and methods of use |
| US9943365B2 (en) | 2013-06-21 | 2018-04-17 | Boston Scientific Scimed, Inc. | Renal denervation balloon catheter with ride along electrode support |
| JP2016524949A (en) | 2013-06-21 | 2016-08-22 | ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． | Medical device for renal nerve ablation having a rotatable shaft |
| US9707036B2 (en) | 2013-06-25 | 2017-07-18 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation using localized indifferent electrodes |
| WO2015002787A1 (en) | 2013-07-01 | 2015-01-08 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
| EP3019096B1 (en) | 2013-07-08 | 2023-07-05 | Avinger, Inc. | System for identification of elastic lamina to guide interventional therapy |
| US10660698B2 (en) | 2013-07-11 | 2020-05-26 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation |
| EP3019106A1 (en) | 2013-07-11 | 2016-05-18 | Boston Scientific Scimed, Inc. | Medical device with stretchable electrode assemblies |
| EP3049007B1 (en) | 2013-07-19 | 2019-06-12 | Boston Scientific Scimed, Inc. | Spiral bipolar electrode renal denervation balloon |
| US10695124B2 (en) | 2013-07-22 | 2020-06-30 | Boston Scientific Scimed, Inc. | Renal nerve ablation catheter having twist balloon |
| WO2015013205A1 (en) | 2013-07-22 | 2015-01-29 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
| JP6159888B2 (en) | 2013-08-22 | 2017-07-05 | ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． | Flexible circuit with improved adhesion to renal neuromodulation balloon |
| US9895194B2 (en) | 2013-09-04 | 2018-02-20 | Boston Scientific Scimed, Inc. | Radio frequency (RF) balloon catheter having flushing and cooling capability |
| CN105530885B (en) | 2013-09-13 | 2020-09-22 | 波士顿科学国际有限公司 | Ablation balloon with vapor deposited covering |
| WO2015057521A1 (en) | 2013-10-14 | 2015-04-23 | Boston Scientific Scimed, Inc. | High resolution cardiac mapping electrode array catheter |
| US11246654B2 (en) | 2013-10-14 | 2022-02-15 | Boston Scientific Scimed, Inc. | Flexible renal nerve ablation devices and related methods of use and manufacture |
| US9770606B2 (en) | 2013-10-15 | 2017-09-26 | Boston Scientific Scimed, Inc. | Ultrasound ablation catheter with cooling infusion and centering basket |
| EP3057520A1 (en) | 2013-10-15 | 2016-08-24 | Boston Scientific Scimed, Inc. | Medical device balloon |
| JP6259099B2 (en) | 2013-10-18 | 2018-01-10 | ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． | Balloon catheter comprising a conductive wire with flexibility, and related uses and manufacturing methods |
| CN105658163B (en) | 2013-10-25 | 2020-08-18 | 波士顿科学国际有限公司 | Embedded thermocouple in denervation flexible circuit |
| WO2015103617A1 (en) | 2014-01-06 | 2015-07-09 | Boston Scientific Scimed, Inc. | Tear resistant flex circuit assembly |
| US10835313B2 (en) | 2014-01-30 | 2020-11-17 | Medlumics S.L. | Radiofrequency ablation catheter with optical tissue evaluation |
| EP3102136B1 (en) | 2014-02-04 | 2018-06-27 | Boston Scientific Scimed, Inc. | Alternative placement of thermal sensors on bipolar electrode |
| US11000679B2 (en) | 2014-02-04 | 2021-05-11 | Boston Scientific Scimed, Inc. | Balloon protection and rewrapping devices and related methods of use |
| CN106102608B (en) | 2014-02-06 | 2020-03-24 | 阿维格公司 | Atherectomy catheters and occlusion crossing devices |
| EP3113701B1 (en) | 2014-03-03 | 2020-07-22 | The Spectranetics Corporation | Multiple configuration surgical cutting device |
| US10912947B2 (en) | 2014-03-04 | 2021-02-09 | Memorial Sloan Kettering Cancer Center | Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells |
| US20170079718A1 (en) | 2014-05-18 | 2017-03-23 | Eximo Medical Ltd. | System for tissue ablation using pulsed laser |
| US10405924B2 (en) | 2014-05-30 | 2019-09-10 | The Spectranetics Corporation | System and method of ablative cutting and vacuum aspiration through primary orifice and auxiliary side port |
| WO2015200702A1 (en) | 2014-06-27 | 2015-12-30 | Covidien Lp | Cleaning device for catheter and catheter including the same |
| EP3166512B1 (en) | 2014-07-08 | 2020-08-19 | Avinger, Inc. | High speed chronic total occlusion crossing devices |
| WO2016012302A1 (en) | 2014-07-22 | 2016-01-28 | Koninklijke Philips N.V. | Tissue sealing device with optical feedback |
| US10688202B2 (en) | 2014-07-28 | 2020-06-23 | Memorial Sloan-Kettering Cancer Center | Metal(loid) chalcogen nanoparticles as universal binders for medical isotopes |
| EP3182917A1 (en) * | 2014-08-20 | 2017-06-28 | Memorial Sloan Kettering Cancer Center | Raman-triggered ablation/resection systems and methods |
| USD765243S1 (en) | 2015-02-20 | 2016-08-30 | The Spectranetics Corporation | Medical device handle |
| USD770616S1 (en) | 2015-02-20 | 2016-11-01 | The Spectranetics Corporation | Medical device handle |
| US10314667B2 (en) | 2015-03-25 | 2019-06-11 | Covidien Lp | Cleaning device for cleaning medical instrument |
| WO2017004301A1 (en) | 2015-07-01 | 2017-01-05 | Memorial Sloan Kettering Cancer Center | Anisotropic particles, methods and uses thereof |
| US10568520B2 (en) | 2015-07-13 | 2020-02-25 | Avinger, Inc. | Micro-molded anamorphic reflector lens for image guided therapeutic/diagnostic catheters |
| US10292721B2 (en) | 2015-07-20 | 2019-05-21 | Covidien Lp | Tissue-removing catheter including movable distal tip |
| US10194981B2 (en) | 2015-07-29 | 2019-02-05 | Medlumics S.L. | Radiofrequency ablation catheter with optical tissue evaluation |
| WO2017042743A1 (en) | 2015-09-09 | 2017-03-16 | Baylis Medical Company Inc. | Epicardial access system & methods |
| US10314664B2 (en) | 2015-10-07 | 2019-06-11 | Covidien Lp | Tissue-removing catheter and tissue-removing element with depth stop |
| EP3407777B1 (en) | 2016-01-25 | 2020-12-30 | Avinger, Inc. | Oct imaging catheter with lag correction |
| CN108882948A (en) | 2016-04-01 | 2018-11-23 | 阿维格公司 | Rotary-cut art conduit with zigzag cutter |
| CN109414292A (en) | 2016-05-05 | 2019-03-01 | 爱克斯莫医疗有限公司 | Device and method for cutting off and/or melting unwanted tissue |
| WO2017210466A1 (en) | 2016-06-03 | 2017-12-07 | Avinger, Inc. | Catheter device with detachable distal end |
| CN109414273B (en) | 2016-06-30 | 2023-02-17 | 阿维格公司 | Atherectomy catheter with shapeable distal tip |
| CA3082622C (en) | 2017-12-05 | 2021-02-02 | Wesley Robert PEDERSEN | Transseptal guide wire puncture system |
| EP4044942A4 (en) | 2019-10-18 | 2023-11-15 | Avinger, Inc. | Occlusion-crossing devices |
| US11759190B2 (en) | 2019-10-18 | 2023-09-19 | Boston Scientific Medical Device Limited | Lock for medical devices, and related systems and methods |
| US11801087B2 (en) | 2019-11-13 | 2023-10-31 | Boston Scientific Medical Device Limited | Apparatus and methods for puncturing tissue |
| US11724070B2 (en) | 2019-12-19 | 2023-08-15 | Boston Scientific Medical Device Limited | Methods for determining a position of a first medical device with respect to a second medical device, and related systems and medical devices |
| US11931098B2 (en) | 2020-02-19 | 2024-03-19 | Boston Scientific Medical Device Limited | System and method for carrying out a medical procedure |
| US11819243B2 (en) | 2020-03-19 | 2023-11-21 | Boston Scientific Medical Device Limited | Medical sheath and related systems and methods |
| US11826075B2 (en) | 2020-04-07 | 2023-11-28 | Boston Scientific Medical Device Limited | Elongated medical assembly |
| US11938285B2 (en) | 2020-06-17 | 2024-03-26 | Boston Scientific Medical Device Limited | Stop-movement device for elongated medical assembly |
| JP2023521165A (en) | 2020-06-17 | 2023-05-23 | ボストン サイエンティフィック メディカル デバイス リミテッド | electroanatomical mapping system |
| US11937796B2 (en) | 2020-06-18 | 2024-03-26 | Boston Scientific Medical Device Limited | Tissue-spreader assembly |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60209146A (en) * | 1984-03-31 | 1985-10-21 | Olympus Optical Co Ltd | Fluorescence spectrochemical analysis device |
| US5106387A (en) * | 1985-03-22 | 1992-04-21 | Massachusetts Institute Of Technology | Method for spectroscopic diagnosis of tissue |
| US4718417A (en) * | 1985-03-22 | 1988-01-12 | Massachusetts Institute Of Technology | Visible fluorescence spectral diagnostic for laser angiosurgery |
| JPH01308544A (en) * | 1988-06-06 | 1989-12-13 | Sumitomo Electric Ind Ltd | Body cavity laser operation apparatus |
| US5197470A (en) * | 1990-07-16 | 1993-03-30 | Eastman Kodak Company | Near infrared diagnostic method and instrument |
| US5163432A (en) * | 1990-07-16 | 1992-11-17 | Matsushita Electric Industrial Co., Ltd. | Catheter type laser illuminating apparatus |
| US5163935A (en) * | 1991-02-20 | 1992-11-17 | Reliant Laser Corporation | Surgical laser endoscopic focusing guide with an optical fiber link |
| WO1993003672A1 (en) * | 1991-08-20 | 1993-03-04 | Redd Douglas C B | Optical histochemical analysis, in vivo detection and real-time guidance for ablation of abnormal tissues using a raman spectroscopic detection system |
| IL100664A0 (en) * | 1992-01-15 | 1992-09-06 | Laser Ind Ltd | Method and apparatus for controlling a laser beam |
| US5439000A (en) * | 1992-11-18 | 1995-08-08 | Spectrascience, Inc. | Method of diagnosing tissue with guidewire |
| DE69432148T2 (en) * | 1993-07-01 | 2003-10-16 | Boston Scient Ltd | CATHETER FOR IMAGE DISPLAY, DISPLAY OF ELECTRICAL SIGNALS AND ABLATION |
| US5608520A (en) * | 1994-07-11 | 1997-03-04 | The United States Of America As Represented By He Department Of Energy | Plasma emission spectroscopy method of tumor therapy |
| US5820627A (en) * | 1996-03-28 | 1998-10-13 | Physical Sciences, Inc. | Real-time optical feedback control of laser lithotripsy |
| US6296608B1 (en) * | 1996-07-08 | 2001-10-02 | Boston Scientific Corporation | Diagnosing and performing interventional procedures on tissue in vivo |
| US5920390A (en) * | 1997-06-26 | 1999-07-06 | University Of North Carolina | Fiberoptic interferometer and associated method for analyzing tissue |
-
1999
- 1999-01-09 US US09/228,030 patent/US6228076B1/en not_active Expired - Lifetime
-
2000
- 2000-01-07 AT AT00904259T patent/ATE548078T1/en active
- 2000-01-07 JP JP2000593228A patent/JP4226788B2/en not_active Expired - Fee Related
- 2000-01-07 AU AU26044/00A patent/AU769737B2/en not_active Ceased
- 2000-01-07 WO PCT/US2000/000460 patent/WO2000041611A2/en active IP Right Grant
- 2000-01-07 KR KR1020017008636A patent/KR100623212B1/en not_active IP Right Cessation
- 2000-01-07 EP EP00904259A patent/EP1146930B1/en not_active Expired - Lifetime
- 2000-01-07 BR BR0007419-5A patent/BR0007419A/en not_active Application Discontinuation
- 2000-01-07 CA CA002355835A patent/CA2355835A1/en not_active Abandoned
- 2000-01-07 IL IL14418300A patent/IL144183A/en not_active IP Right Cessation
-
2002
- 2002-04-06 HK HK02102564.0A patent/HK1040648A1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107727636A (en) * | 2017-10-13 | 2018-02-23 | 中国科学院上海技术物理研究所 | It is a kind of that serum analysis method is frozen based on the ultraviolet Raman fluorescence Spectra of time domain resolution |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000041611A3 (en) | 2000-11-30 |
| ATE548078T1 (en) | 2012-03-15 |
| BR0007419A (en) | 2001-10-16 |
| US6228076B1 (en) | 2001-05-08 |
| EP1146930B1 (en) | 2012-03-07 |
| EP1146930A4 (en) | 2003-02-19 |
| WO2000041611A2 (en) | 2000-07-20 |
| AU769737B2 (en) | 2004-02-05 |
| JP2002534199A (en) | 2002-10-15 |
| JP4226788B2 (en) | 2009-02-18 |
| IL144183A (en) | 2005-12-18 |
| KR20010101426A (en) | 2001-11-14 |
| AU2604400A (en) | 2000-08-01 |
| IL144183A0 (en) | 2002-05-23 |
| HK1040648A1 (en) | 2002-06-21 |
| KR100623212B1 (en) | 2006-09-12 |
| EP1146930A2 (en) | 2001-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1146930B1 (en) | System for controlling tissue ablation | |
| US5951482A (en) | Assemblies and methods for advancing a guide wire through body tissue | |
| JP2002534199A5 (en) | ||
| US8046057B2 (en) | Tissue structure identification in advance of instrument | |
| US6451009B1 (en) | OCDR guided laser ablation device | |
| US20080125634A1 (en) | Method and apparatus for identifying and treating myocardial infarction | |
| US8670813B2 (en) | Systems and methods for analysis and treatment of an occluded body lumen | |
| JP5090176B2 (en) | Real-time evaluation system for tissue ablation | |
| US20010027316A1 (en) | Myocardial revascularization-optical reflectance catheter and method | |
| US20050159731A1 (en) | Intravascular catheter | |
| JPH09117407A (en) | Optical fiber spectrum catheter | |
| US20200397378A1 (en) | Apparatus and methods for optical position sensing | |
| US20160183804A1 (en) | Laser catheter with use of reflected light to determine material type in vascular system | |
| US10646275B2 (en) | Laser catheter with use of determined material type in vascular system in ablation of material | |
| US20100069760A1 (en) | Methods and apparatus for analyzing and locally treating a body lumen | |
| EP3282928B1 (en) | Detection of anisotropic biological tissue | |
| US20210045721A1 (en) | Surgical instrument and surgical system | |
| WO2023126344A1 (en) | Fiber-optic medical treatment apparatus for treatment of a urinary tract of a subject | |
| IL290669A (en) | Detection of balloon catheter tissue contact using optical measurement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |